Did You Know...
...that Thomas Edison's patent application on his phonograph was approved by the Patent Office in just seven weeks? In contrast, it took Gordon Gould, the inventor of the laser, 30 years to obtain his patent -- finally awarded in 1988!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8093396 | Benzthiazole inhibitors of poly(ADP-ribose)polymerase Inhibitors of poly(ADP-ribose)polymerase having a structure of Formula (I), ways to make them and methods of treating patients using them are disclosed. ... | 01/10/2012 |
| 8013166 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity This invention relates to certain aryl alkyl acid compounds, compositions, and methods for treating or preventing obesity and related diseases. ... | 09/06/2011 |
| 7482466 | Hydroxamates as therapeutic agents The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase... | 01/27/2009 |
| 7423156 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity This invention relates to certain aryl alkyl acid compounds, compositions, and methods for treating or preventing obesity and related diseases. ... | 09/09/2008 |
| 7378397 | TRH-degrading ectoenzyme inhibitors Peptide derivatives useful as inhibitors of activity of thyrotropin-releasing hormone-degrading ectoenzyme (TRH-DE) are of formula Ia: wherein: R1 is an optionally su... | 05/27/2008 |
| 7374749 | Amino substituted hydroxyphenyl benzophenone derivatives Described are amino substituted hydroxyphenyl benzophenone derivatives of formula (I), wherein R1, and R2 independently from each other are; C1-C20alkyl; C2-C20-alken... | 05/20/2008 |
| 7358254 | Method for treating atherosclerosis employing an aP2 inhibitor and combination A method is provided for treating atherosclerosis and related diseases, employing an aP2 inhibitor or a combination of an aP2 inhibitor and another antiatherosclerotic agent, for example, an HMG CoA reductase inhibitor such as pravastatin. ... | 04/15/2008 |
| 7358373 | Cathepsin K inhibitors The present invention provides a compound of the Formula: a pharmaceutically acceptable salt, a solvate, or a prodrug thereof, wherein m, n, Ar1, R1, R2, R3, R4, and R | 04/15/2008 |
| 7348347 | Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds Substituted 4,5,6,7-tetrahydrobenzothiazol-2-ylamine compounds, a method for their production; pharmaceutical compositions comprising them, and methods of use for modulating biological functions and/or treating or inhibiting various medical conditions such as, e.g.,... | 03/25/2008 |
| 7312211 | Pryanone compounds useful as reversible inhibitors of cysteine proteases Disclosed are cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (Ia) and (Ib) where R2, R3, R4, R6, R8 and Y are defined herein. The compounds are useful for treating autoimmune and othe... | 12/25/2007 |
| 7189749 | Substituted phenoxyacetic acids Disclosed are substituted phenoxyacetic acids useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds, alone or in combination with other therapeutic agents, and methods... | 03/13/2007 |
| 7157454 | Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same The invention relates to compounds of formula: These compounds show affinity for the bradykinin receptors with selectivity towards the B1 receptors; they may be used for the preparation of medicinal pr... | 01/02/2007 |
| 7157585 | Serine protease inhibitors Compounds of formula (I) where R5, R6a, each X, L, Cy and Lp are as defined in the specification, are tryptase inhibitors useful as antiinflammatory agents. ... | 01/02/2007 |
| 7141312 | Organic electroluminescent device based on 2,5-diaminoterephthalic acid derivatives The application relates to an organic electroluminescent device which contains 2,5 diaminoterephthalic acid derivatives of formula 1a as emitter substances in one or several emitter layers in a pure or doped manner. The ring A is a triple unsaturated benzene ... | 11/28/2006 |
| 7115640 | Heterocyclic modulators of nuclear receptors Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of farnesoid X receptor (FXR), liver X receptor (LXR) and/or orphan nuclear receptors. I... | 10/03/2006 |
| 7112674 | Organic electroluminescent device based on 2,5-diaminoterephthalic acid derivatives The invention relates to an organic electroluminescent device which contains 2,5-diaminoterephthalic acid derivatives of formula 1a as emitter substances in one or several emitter layers in a pure or doped manner. The ring A is a triple unsaturated benzene ring wher... | 09/26/2006 |
| 7112598 | κ opioid receptor agonist comprising 2-phenylbenzothiazoline derivative A compound or a salt thereof having the following formula wherein R1 is acyl, R2 is hydrogen, halogen, unsubstituted alkyl or alkyl substituted by halogen; R3 is halogen or alkoxy... | 09/26/2006 |
| 7105564 | Pharmaceutical composition comprising a dual antagonist against PGD/TXAreceptors having a [2.2.1] or [3.1.1] bicyclic skeleton The present invention provides novel compounds having a dual antagonistic activity against thromboxane A2 receptor and prostaglandin D2 receptor and pharmaceutical compositions comprising them. A compound of the formula (I): | 09/12/2006 |
| 7030239 | Compounds to treat Alzheimer's disease The present invention is directed toward substituted hydroxyethylene compounds of formula (XII) useful in treating Alzheimer's disease and other similar diseases. ... | 04/18/2006 |
| 6995262 | Use of acylsulfonamido-substituted polymethine dyes as fluorescene dyes and/or markers The invention relates to a novel polymethine dyes containing at least one acylsulfonamido group of the formula (I) in which n, Y, A and R have the meaning given in the claims, and at least one compound of the formulae ... | 02/07/2006 |
| 6967251 | Reagents for labeling biomolecules having aldehyde or ketone moieties Novel fluorescent derivitization reagents are described that are suitable for coupling to biomolecules that contain aldehyde or ketone functional groups. In one embodiment is provided reagents that have the following formula: | 11/22/2005 |
| 6960591 | Propane-1,3-dione derivative Provided is a pharmaceutical composition containing a propane-1,3-dione derivative as the active ingredient, particularly a GnRH receptor antagonist. Also, provided is a propane-1,3-dione derivative having a GnRH antagonistic effect. ... | 11/01/2005 |
| 6900218 | Pyruvate derivatives Certain known and novel pyruvate derivatives are particularly active in restoring or preserving metabolic integrity in oxidatively competent cells that have been subjected to oxygen deprivation. These pyruvate-derived compounds include, but are not limited to oximes... | 05/31/2005 |
| 6891043 | Inhibitors of fatty acid amide hydrolase Potent inhibitors of fatty acid amide hydrolase (FAAH) are constructed having K1's below 200 pM and activities 102-103 times more potent than the corresponding trifluoromethyl ketones. The potent inhibitors combine several features, ... | 05/10/2005 |
| 6759428 | Indole nitriles Compounds of the formula (I) wherein m, n, R1, R2, R3, R4, R5 and R6 are as described herein, together with methods for making the compounds and using the... | 07/06/2004 |
| 6747053 | Heteroaryl nitriles The present invention relates to compound of formula (I) wherein R1, R2, R3, R4, R5 and n are as defined in the description and claims and pharmaceutically acceptabl... | 06/08/2004 |
| 6706744 | Glucagon antagonists/inverse agonists Novel compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein... | 03/16/2004 |
| 6706735 | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases. ... | 03/16/2004 |
| 6703347 | Isothiazole derivatives and their use as pesticides A compound of formula (I), where A is optionally substituted alkylene, alkenylene, alkynylene, cycloalkylene, alkylenoxy, oxy(C1-6)alkylene, alkylenthio, thio(C1-6)alkylene, C1-6 alkylenamino, amino(C1-6)alkylen... | 03/09/2004 |
| 6696473 | Heterocyclic modulators of nuclear receptors Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of farnesoid X receptor (FXR), liver X receptor (LXR) and/or orphan nuclear r... | 02/24/2004 |
| 6677365 | Antagonists of MCP-1 function and methods of use thereof Chemical compounds which are antagonists of Monocyte Chemoattractant Protein-1 (MCP-1) function, pharmaceutical compositions comprising these compounds, methods of treatment employing these compounds and compositions, and processes for preparing these com... | 01/13/2004 |
| 6603014 | Use of cyclic enamines as light protection agents The use of compounds of the formula I ##STR1## in which R1 and R2 are identical or different, electron-withdrawing radicals chosen from the group consisting of cyano, alkyl- or arylcarbonyl, alkyloxy- or aryloxycarbonyl and optionall... | 08/05/2003 |
| 6576765 | Process for preparing amic acid esters The present invention provides a process for producing an amic acid ester represented by the following general formula (7) (wherein A is substituted or unsubstituted lower alkylene or the like; R1 is substituted or unsubstituted lower alkyl or ... | 06/10/2003 |
| 6541016 | Mixtures of alkylphosphoric esters and use thereof as cosmetic and pharmaceutical emulsifiers This invention relates to monoalkyl phosphoric esters, dialkyl phosphoric esters, and, in small amounts, trialkyl phosphoric esters or salts thereof, which are preferably based on ଲ-branched fatty alcohols, particularly Guerbet alcohol, which are ef... | 04/01/2003 |
| 6538016 | -sulfin-and -sulfonamino acid amides The invention relates to -sulfin- and -sulfonamino acid amides of the general formula I ##STR1## including the optical isomers thereof and mixtures of such isomers, wherein n is a number zero or one; R1 is C1 -C12... | 03/25/2003 |
| 6534530 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis Compounds of the formula: ##STR1## where the formula variables are as defined in the disclosure, advantageously inhibit or block the biological activity of the picornaviral 3C protease. These compounds, as well as pharmaceutical compositions containi... | 03/18/2003 |
| 6531474 | Inhibitors of caspases The present invention relates to novel classes of compounds which are caspase inhibitors, in particular interleukin-1ଲ converting enzyme ("ICE") inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The c... | 03/11/2003 |
| 6525203 | Heterocyclic aromatic compounds useful as growth hormone secretagogues Heterocyclic aromatic compounds are provided which are useful in stimulating endogenous production or release of growth hormone and in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength. The heterocycl... | 02/25/2003 |
| 6518292 | Heterocyclic aromatic compounds usefuls as growth hormone secretagogues Heterocyclic aromatic compounds are provided which are useful in stimulating endogenous production or release of growth hormone and in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength. The heterocycl... | 02/11/2003 |
| 6515124 | Dehydroamino acids Aromatic dehydroamino acids are disclosed that are active as LFA-1 arnagonists This activity enables these compounds to prevent inflammation which is a consequence of T cell activation and accordingly reduce or eliminate inflammatory skin disease psoriasi... | 02/04/2003 |
